Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma
Yuan-hong Huang, Chao‐Ling Wan, Haiping Dai, et al.
Annals of Hematology (2023) Vol. 102, Iss. 8, pp. 2001-2013
Closed Access | Times Cited: 12

Showing 12 citing articles:

Developing a Competency Assessment Index System for Hematology Nurses in China
Baohui Xu, D C Gu, Yun Wu, et al.
Clinical Nurse Specialist (2025) Vol. 39, Iss. 2, pp. 91-98
Closed Access
Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China
Lan Luo, Yang Jiao, Yan Li, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 2073-2087
Closed Access | Times Cited: 3
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia
Fangfei Xu, Xichang Bao, Wei Huang, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Pediatric oncology drug development and dosage optimization
S. Y. Amy Cheung, Justin L. Hay, Yu-Wei Lin, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 3
Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia
Syeda Saliah Hussan, Muhammad Ali, Mishal Fatima, et al.
Annals of Hematology (2023) Vol. 103, Iss. 2, pp. 511-523
Closed Access | Times Cited: 4
CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory/Relapsed T-ALL/LBL
Zhihui Li, Qinlong Zheng, Keyan Yang, et al.
Transplantation and Cellular Therapy (2024)
Closed Access | Times Cited: 1
CD7 Nanobody-Based Immuno-Nanotoxin for Targeted Treatment of T-Cell Acute Lymphoblastic Leukemia
Yangyang Dong, Fengtao You, Yifan Zhang, et al.
ACS Applied Nano Materials (2024) Vol. 7, Iss. 7, pp. 7195-7202
Closed Access | Times Cited: 1
Lupiwighteone as an Antitumor Agent Reverses Multidrug Resistance in K562/ADR Cells by Regulating Cellular Prion Protein-Oct4 Axis
Kun Hu, Jinling Zhang, Yanan Zhang, et al.
Anti-Cancer Agents in Medicinal Chemistry (2024) Vol. 24, Iss. 20, pp. 1514-1524
Closed Access
CDK6: an attractive therapeutic target for T-ALL/LBL
Wei Li, Jamie K. Hu, Miaofen G. Hu
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 11, pp. 1087-1096
Closed Access | Times Cited: 1
Elderly ALL: Low-Dose Chemotherapy and Immunotherapy Combinations
Patrice Chevallier
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, pp. S34-S36
Closed Access
Abordagem no Tratamento da Leucemia Linfoblástica Aguda em Pediatria: Monitoramento e perspectivas
P. C. Ramos, Yasmin Suassuna Lacerda de Vasconcelos, Lizanka Dias Abrantes, et al.
Brazilian Journal of Implantology and Health Sciences (2023) Vol. 5, Iss. 5, pp. 5327-5341
Open Access
Evaluating the Use of Large Language Model to Identify Top Research Priorities in Hematology
Huiqin Chen, Fangwan Huang, Xuanyun Liu, et al.
(2023)
Closed Access
Page 1

Scroll to top